Clinical Research Papers:
Effect of the asthma–chronic obstructive pulmonary disease syndrome on the stroke, Parkinson's disease, and dementia: a national cohort study
Metrics: PDF 678 views | HTML 1953 views | ?
Jun-Jun Yeh1,2,3,4,*, Yu-Feng Wei5, Cheng-Li Lin6,7 and Wu-Huei Hsu8,9,*
1Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi, Taiwan
2Chia Nan University of Pharmacy and Science, Tainan, Taiwan
3Meiho University, Pingtung, Taiwan
4Pingtung Christian Hospital, Pingtung, Taiwan
5Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan
6Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan
7College of Medicine, China Medical University, Taichung, Taiwan
8Graduate Institute of Clinical Medical Science and School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan
9Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan
*These authors contributed equally to this work
Wu-Huei Hsu, email: email@example.com
Jun-Jun Yeh, email: firstname.lastname@example.org
Keywords: asthma–chronic obstructive pulmonary disease syndrome (ACOS); stroke; Parkinson's disease (PD); dementia; inhaler steroids
Received: April 25, 2017 Accepted: November 10, 2017 Published: December 26, 2017
Background: To evaluate the association of asthma–chronic obstructive pulmonary disease syndrome (ACOS) with neurodegenerative diseases (stroke, Parkinson's disease and dementia) and the role of the steroids in the neurodegenerative diseases among the ACOS cohort.
Materials and Methods: Comparison of the ACOS cohort (N = 10,260) with the non-ACOS cohort (n = 20,513) based on the patients aged ≧40 years in the National Health Insurance Research Database from January 1, 2000 to December 31, 2010. These patients follow up to diagnosis of neurodegenerative diseases or the December 31, 2011; using multivariable Cox proportional hazards models.
Results: After adjustment for potential confounders, the [adjusted hazard ratio (aHR), 95% confidence interval (CI)] in the ACOS cohort were [1.39, 1.28–1.50] [1.56, 1.34–1.81] and [1.43, 1.29–1.59] for stroke, Parkinson's disease, dementia; respectively. The [aHR, 95% CI] for ACOS cohort with (inhaler corticosteroids ≧0.13 gram/ oral steroids ≧0.08gram) were with less risk (all aHR<1, p values <0.05) for these 3 neurodegenerative diseases except Parkinson's disease with inhaler corticosteroids >0.43 gram. The risk of stroke and dementia were the lower in patients with < 250 μg/d of a fluticasone equivalent inhaler corticosteroids (aHR = 0.53, 95% CI = 0.35–0.79; aHR = 0.53, 95% CI = 0.31–0.90, respectively).
Conclusions: The ACOS cohort had a higher risk of the neurodegenerative diseases. The lower dose of the inhaler corticosteroids with cumulative dose ≧0.13 gram have the less risk of stroke and dementia.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.